RE: No News24 Jun 2024 18:12
I hear you, Tommy. And I agree it sounds positive. But I also remember my now very cringeworthy reasons to invest in Synairgen pre P3 fail, a trimmed down version below:
- Previous trial results, including advancement to phase 3 in ACTIV US trial, are supportive of a positive outcome.
- Recent recruitment drive to senior positions.
- Brokers positive. Numis price target of £9.90, Dr Paul Cuddon experienced in covering such stocks. Finncap also positive.
- Polygon/Polar taking significant stakes in Synairgen.
- Commercialisation agreement signed with Ashfield, owned by UDG Healthcare (former FTSE250 member before being bought out in 2021).
- Several senior job roles advertised focusing on the US.
- Synairgen Incorporated set up in the US post P3 data being received.
- Video from Synairgen on 17/01/22 saying “we’re ready”.
- Ray Jordan PR guy signing up.
As we can see, Synairgen were full steam ahead, recruitment drives, PR deals, videos saying “we’re ready”, new companies incorporated in the US… it looked nailed on. So there’s form with regards to recruitment and getting ahead of themselves, at the very least.
Playing Devil’s advocate, has RM got a bit excited again thinking the P2’s would have been a formality, done and dusted quickly and onto a P3, but in reality it’s all going very slowly and Spacman finally has one of his many dozens of theories right, those pesky auditors now not happy with the financial outlook and trials costing more than first thought? And if so, what now? They’ve pi.55ed off the regular PI to the point they won’t get a penny there etc etc, TFG not willing to stump up unless they get 90% of the company, Dragon’s Den style, which PI’s would never accept.
For me, it’s now got to the point where this has been written off, and I’m more intrigued now with how this epic tale ends.